OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
16-Week Randomized Double-Blind Placebo Controlled Parallel-Group Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day in Adolescents With Bilateral Nasal Polyps Followed With 12-Week Open-Label Treatment Phase
Sponsor: Optinose US Inc.
Listed as NCT03747458, this PHASE3 trial focuses on Bilateral Nasal Polyposis and remains actively recruiting participants. Sponsored by Optinose US Inc., it has been updated 22 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
22 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE3
-
Oct 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE3
▶ Show 17 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Apr 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
May 2022 — Apr 2023 [monthly]
Recruiting PHASE3
-
Feb 2021 — May 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2019 — Sep 2020 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Optinose US Inc.
For direct contact, visit the study record on ClinicalTrials.gov .